Chiusura precedente | 0,0706 |
Aperto | 0,1290 |
Denaro | 0,0000 x N/D |
Lettera | 0,0000 x N/D |
Min-Max giorno | 0,1290 - 0,1290 |
Intervallo di 52 settimane | 0,1290 - 0,1290 |
Volume | |
Media Volume | N/D |
Capitalizzazione | N/D |
Beta (5 anni mensile) | -0,46 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,0240 |
Prossima data utili | N/D |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Initial A4100 code being deployed and application for specific HCPCS product code to be submitted in the second calendar quarterFRAMINGHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided an update regarding its reimbursement strategy for the use of AC5® Advanced Wound System (“AC5”), specifically regarding its use in doctor’s offices and
World-renowned Wound Care Leaders, Terry Treadwell, MD, FACS and Brock Liden, DPM, Shared Insights on Success with AC5® Advanced Wound SystemFRAMINGHAM, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, announced today that the third interview in the Experts in Wound Care Program, a series of interviews with key opinion leaders dedicated to advancing wound
Additional data covered a variety of specialties, including vascular surgery, plastic surgery, general surgery, and podiatry, to further support clinical efficacy of AC5® Advanced Wound System in acute, chronic, and challenging wounds.FRAMINGHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that two clinical case reports on the use of